Cellular Therapy with Autologous Mesenchymal Stromal Cells in Patients with Drug Resistant Pulmonary Tuberculosis
https://doi.org/10.58838/2075-1230-2023-101-6-74-80
Abstract
The objective: to evaluate the effectiveness of treatment with autologous mesenchymal stromal cells (MSCs) in patients with drug resistant pulmonary tuberculosis (DR TB).
Subjects and Methods. 120 patients with drug resistant tuberculosis aged 18 to 61 years old were enrolled in the study. They all were treated at the Republican Scientific and Practical Center of Pulmonology and Phthisiology from 2009 to 2018. Against the background of anti-tuberculosis treatment, patients (60 people) from Main Group (MG) underwent bone marrow sampling and then intravenous administration of autologous MSCs.
Results. The average dose of administered cells was 1x106 per kg of the patient body weight. The average duration of MSC cultivation made 35 days. Treatment effectiveness in MG made 90% versus 71% in Control Group (CG). All patients who were successfully cured of tuberculosis (TB) using autologous MSCs had no tuberculosis relapses during 5 years of follow-up. In Control Group, 8 (19%) cases of relapse were reported. In Main Group versus Comparison Group, the rates indicating healing of cavities and absence of relapse are statistically significantly better.
Conclusion. The use of autologous MSCs in patients with drug resistant tuberculosis has shown its high effectiveness.
About the Authors
V. V. Solodovnikova
Republican Scientific and Practical Center of Pulmonology and Phthisiology
Belarus
Belarus
Varvara V. Solodovnikova, Senior Researcher of Department for Laboratory Diagnostics and Treatment of Tuberculosis
157, Dolginovsky Road, Minsk, 220053
Phone: +3 (7529) 343-77-51
A. E. Skryagin
Belarusian State Medical University
Belarus
Belarus
Aleksander E. Skryagin, Candidate of Medical Sciences, Associate Professor of Anesthesiology and Intensive Care Department
83 Dzerzhinskogo Ave., Minsk, 220083
Y. I. Isaykina
Republican Scientific and Practical Center of Children's Oncology, Hematology and Immunology
Belarus
Belarus
Yanina I. Isaykina, Candidate of Biological Sciences, Head of Laboratory of Cellular Biotechnologies and Cytotherapy
43 Frunzenskaya St., Borovlyany, Minsky District, 223053
Phone: +3 (8017) 505-27-17
D. A. Klimuk
Republican Scientific and Practical Center of Pulmonology and Phthisiology
Belarus
Belarus
Dmitry A. Klimuk, Head of Department of Phthisiopulmonology Monitoring and Evaluation
157, Dolginovsky Road, Minsk, 220053
Phone: +3 (7529) 982-32-66
G. L. Gurevich
Republican Scientific and Practical Center of Pulmonology and Phthisiology
Belarus
Belarus
Gennady L. Gurevich, Doctor of Medical Sciences, Professor, Correspondent Member of the Belarus National Academy of Sciences, Director
157, Dolginovsky Road, Minsk, 220053
E. M. Skryagina
Republican Scientific and Practical Center of Pulmonology and Phthisiology
Belarus
Belarus
Elena M. Skryagina, Doctor of Medical Sciences, Professor, Deputy Director for Research
157, Dolginovsky Road, Minsk, 220053
References
1. Caplan A., Dennis J.E. Mesenchymal stem cells as trophic mediators // J. Cell Biochem. – 2006. – Vol. 98, №5, P. – 1076–1084.
2. Chow L., Johnson V., Impastato R., et al. Antibacterial activity of human mesenchymal stem cells mediated directly by constitutively secreted factors and indirectly by activation of innate immune effector cells // Stem Cells Transl. Med. –2019. – Vol. 9, №2, P. – 235–249.
3. Furin J., Cox H., Pai M. Tuberculosis // Lancet. – 2019. – Vol. 393. – P. 1642-1656.
4. Global tuberculosis report 2022. – Geneva: World Health Organization, 2022. – P. 68.
5. Korbling M., Estrov Z. Adult stem cells fo rtissue repair − a new therapeutic concept // N. Engl. J. Med. – 2003. – Vol. 349, № 6. – P. 570-582.
6. Lai R.C., Arslan F., Lee M.M., et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury // Stem Cell Res. – 2010. – Vol. 4, № 3, P. – 214–222.
7. Mahardani P.N., Wati D.K., Siloam A., et al. Effectiveness and safety of short-term regimen for multidrug-resistant tuberculosis treatment: a systematic review of cohort studies // Oman Medical Journal. – 2022. – Vol. 37, № 1. – P. 337.
8. Meisel R., Brockers S., Heseler K., et al. Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase // Leukemia. – 2011. – Vol. 25, № 4. – P. 648–654.
9. Moravej A., Kouhpayeh A., Geramizadeh B. et al. The Effect of Mesenchymal Stem Cells on the Expression of IDOand Qa2 Molecules in Dendritic Cells // Advanced Pharmaceutical Bulletin. – 2019. – Vol. 9, № 1. – P. 56–63.
10. Skrahin A., Jenkins H.E., Hurevich H., et al. Effectiveness of a novel cellular therapy to treat multidrug-resistant tuberculosis // J Clin. Tuberc. Other Mycobact. Dis. – 2016. – № 4. – P. 21-27.
Review
For citations:
Solodovnikova V.V., Skryagin A.E., Isaykina Y.I., Klimuk D.A., Gurevich G.L., Skryagina E.M. Cellular Therapy with Autologous Mesenchymal Stromal Cells in Patients with Drug Resistant Pulmonary Tuberculosis. Tuberculosis and Lung Diseases. 2023;101(6):74-80. (In Russ.) https://doi.org/10.58838/2075-1230-2023-101-6-74-80
Views:
321
Email this article 